Gilead Sciences (GILD) Cash from Financing Activities (2009 - 2026)

Gilead Sciences (GILD) has reported Cash from Financing Activities for 18 consecutive years, with -$4.2 billion the latest figure, recorded in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$4.2 billion, down 23.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.6 billion (down 55.66% YoY), and the FY2025 annual result was -$7.7 billion, down 125.6% from the prior year.
• Cash from Financing Activities was -$4.2 billion for Q1 2026 at Gilead Sciences, down from -$1.3 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $2.3 billion in Q4 2024 and troughed at -$4.2 billion in Q1 2026.
• Average Cash from Financing Activities over 5 years is -$1.6 billion, with a median of -$1.5 billion recorded in 2025.
• The widest YoY moves for Cash from Financing Activities: up 305.64% in 2024, down 168.21% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$1.6 billion in 2022, then grew by 29.28% to -$1.1 billion in 2023, then soared by 305.64% to $2.3 billion in 2024, then plunged by 155.88% to -$1.3 billion in 2025, then tumbled by 235.63% to -$4.2 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$4.2 billion in Q1 2026, -$1.3 billion in Q4 2025, and -$1.5 billion in Q3 2025.